Pfizer's prostate cancer drug combination gets FDA priority review
PFE•FDA grants priority review to Pfizer application
Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its application seeking to expand approval of its prostate cancer treatment combination.
